Background {#Sec1}
==========

Neurogenic inflammation (NI) has for decades been considered an important part of migraine pathophysiology \[[@CR1]\]. Basic studies of NI show that it is characterized by proinflammatory responses, caused by the stimulation of peripheral terminals of the primary sensory neurons located in the trigeminal ganglion \[[@CR2]\], ultimately involved in sensitization and allodynia. Despite growing interest on the role of neuro-immune interactions in migraine, studies show controversial results regarding serum cytokine levels \[[@CR3]--[@CR5]\].

An interaction between the kynurenine pathway and the immune system has been suggested \[[@CR6]\]; the kynureninine system by itself can be activated by inflammatory agents and kynurenic acid has a clear antiinflammatory effect \[[@CR7]\]. One of the first studies demonstrating that the kynurenine pathway has a central role in migraine, was performed by Knyihár-Csillik and coworkers, revealed that electrical stimulation of the trigeminal ganglion decreased kynurenine-aminotransferase immunoreactivity in rat dura mater \[[@CR8]\]. Recent studies strengthen the importance of the kynurenine system in case of primary headaches, showing significant reduction in levels kynurenic acid in patients with chronic migraine \[[@CR9]--[@CR11]\].

In order to advance our understanding we have developed a method to study inflammation in the trigeminal ganglion induced by local dural application of Complete Freund's Adjuvant (CFA) \[[@CR12]\].

In the present study we administered a novel kynurenic acid analogue (SZR72), a glutamate antagonist, to demonstrate its ability to modify this trigeminal ganglion response and might therefore represent a future approach to migraine treatment.

Methods {#Sec3}
=======

The present study is based on the animal model of inducing inflammatory response in the trigeminal ganglion via activation of the peripheral branches in the dura mater of the trigeminal neurons \[[@CR12]\].

Synthesis of novel KYNA derivative {#Sec4}
----------------------------------

The KYNA amide was designed in the Department of Pharmaceutical Chemistry and MTA-SZTE Research Group for Stereochemistry, University of Szeged Hungary. The synthesis was performed by coupling of KYNA and 2-dimethylaminoethylamine, afterwards treatment of ethanolic hydrogen chloride, resulting *N*-(2-*N*,*N*-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride. The structural properties of SZR72 are the following: presence of a water-soluble side-chain, the inclusion of a new cationic center, and side-chain substitution in order to facilitate brain penetration \[[@CR6], [@CR13]\].

Animals {#Sec5}
-------

Adult male Sprague-Dawley rats (220--300 g) (*n* = 49, 24 for immunohistochemistry, 25 for Western blot) were used. The animals were maintained under standard laboratory conditions with free access to food and tap water. The study followed the guidelines of the European Communities Council (86/609/ECC) and approved by the Ethics Committee of The Faculty of Medicine, University of Szeged, Hungary.

Operations {#Sec6}
----------

We have recently described the method in detail \[[@CR12]\].

Treatments {#Sec7}
----------

The animals were divided into 5 groups: (i) pre-treatment KYNA (KYNA analog 1 h before CFA administration), (ii) pre-treatment saline (saline 1 h before CFA), (iii) repeated treatment (KYNA analog every 12 h, for 7 days), (iv) repeated saline (saline every 12 h, for 7 days) and (v) fresh (intact, control rats) (Table [1](#Tab1){ref-type="table"}). The KYNA analog (300 mg/kg body weight was dissolved in 1 ml saline) or saline (1 ml) were given intraperitoneally.Table 1Animal groups used for immunohistochemistry and Western blotGroupsTreatment 1 h before operationTreatment every 12 hrs, for 7 daysNo of animals, IHCNo of animals, WBPre-treatment SZR72KYNA derivate-65Pre-treatment salinesaline-45Repeated treatment SZR72KYNA derivateKYNA derivate65Repeated salinesalinesaline45Intact control\--45

As shown before \[[@CR12]\] the "inflammatory" response to dural CFA was studied after 1 week, left trigeminal ganglion was removed and the specimens were prepared for immunohistochemistry or Western blot.

Immunohistochemistry and microscopic analysis {#Sec8}
---------------------------------------------

Immunohistochemistry was performed to demonstrate the localization of pERK1/2 and IL-1β, and semi-quanitatively evaluate the alterations in their expression in the trigeminal ganglion. Details of the antibodies are given in Table [2](#Tab2){ref-type="table"}. The immunohistochemistry method and the microscopic analysis were described in our previous study \[[@CR12]\].Table 2Details of primary and secondary antibodies used for IHC and WBNameProduct codeHostDilutionCompanyIHCPhospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)4376Rabbit1:50Cell Signaling Technology, Danvers, MA, USAAnti IL-1 beta antibodyab 9787Rabbit1:100Abcam; Cambridge, UKWBPhospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)4376Rabbit1:1000Cell Signaling Technology, Danvers, MA, USAAnti IL-1 beta antibodyab 9787Rabbit1:500Abcam; Cambridge, UK

Western blot {#Sec9}
------------

The method used for Western blot is described in one of our studies \[[@CR14]\]. Data were normalised to an internal loading control sample to adjust for gel-to-gel variation and both pERK and pro-IL1beta calculated relative to t-ERK.

Findings {#Sec10}
========

Immunohistochemistry {#Sec11}
--------------------

In evaluating the immunohistochemical results, the medullary zone of the trigeminal ganglion and the V1 region were chosen.

pERK1/2 {#Sec12}
=======

As described earlier \[[@CR12]\], pERK1/2 immunoreactivity was detected in a few nuclei of the neurons, including nucleoli, in fresh animals. A few satellite glial cells (SGC) were considered as positively stained (Fig. [1a](#Fig1){ref-type="fig"}). In CFA treated animals i.p. saline revealed high-intensity pERK1/2 immunoreactivity in SGCs, especially in the anteromedial zone of the ganglion (Fig. [1b](#Fig1){ref-type="fig"}). No significant difference was noted in case of repeated use of saline i.p.Fig. 1pERK1/2 in the trigeminal ganglion. **a** In fresh animals, pERK1/2 immunoreactivity was detected in a few nuclei of the trigeminal ganglia, including nucleoli, in fresh animals. No immunoreactivity was found in the neuronal cytoplasm. A few SGC were considered as positively stained. **b** In CFA animals repeated treatment with saline i.p., high-intensity pERK1/2 immunoreactivity was observed in SGCs. **c** Animals treated with KYNA for 7 days, diminished immunoreactivity to pERK1/2 in SGC

In contrast, animals treated with the novel KYNA derivate, showed abolished pERK1/2 immunoreactivity in SGC (Fig. [1c](#Fig1){ref-type="fig"}). Repeated treatment with the KYNA analog resulted in mitigation of the SGC activation compared to saline treatment; both positive and negative SGC were detected.

Blinded analysis of the SGCs fluorescence intensity showed significant difference between the control groups and the pre-treatment group with KYNA derivate (*p* \< 0.05). In contrast, no significant difference between the control groups and repeated treatment with KYNA analog was found (*p* = 0.069), neither between the pre-treatment and repeated treatment groups with KYNA analog (*p* = 0.567).

IL-1β {#Sec13}
=====

As described before \[[@CR12]\], IL-1β immunoreactivity was observed in the neuronal cytoplasm (in a granular manner), in a few nuclei and in the nerve fibers of fresh animals. No immunoreactivity was detected in the SGC (Figs. [2a](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). After i.p. treatment with saline and application of CFA, increased IL-1β immunoreactivity was observed both intracellularly in the neurons, and in the fibers. In addition, a "ring" IL-1β immunoreactivity close to the neuronal cell membrane was evident, which differed from the granular pattern seen in fresh animals (Fig. [2b](#Fig2){ref-type="fig"}).Fig. 2IL-1β in the trigeminal ganglion. **a** IL-1β immunoreactivity was observed in the neuronal cytoplasm (in a granular manner), in a few nuclei and in the nerve fibers of fresh animals. No immunoreactivity was detected in the SGC. **b** After i.p. treatment with saline for 7 days, increased IL-1β immunoreactivity was observed both intracellularly in the neurons, and in the fibers. In addition, a "ring" IL-1β immunoreactivity close to the neuronal cell membrane was evident. **c** Following i.p. treatment with KYNA for 7 days, the homogenous immunoreactivity close to the cell membrane disappeared, returning to the granular cytoplasmatic pattern observed in fresh animals. No difference could be noted in the neuronal nuclei and in fibers, and no immunoreactivity was detected in the SGCFig. 3A detailed distribution of IL-1β in a trigeminal ganglion neuron

Following i.p. treatment with KYNA analogue, the homogenous immunoreactivity close to the cell membrane disappeared, returning to the granular cytoplasmatic pattern observed in fresh animals. Repeated treatment with KYNA derivate showed no difference compared to the pretreatment with KYNA. No difference could be noted in the neuronal nuclei and in fibers, and no immunoreactivity was detected in the SGC (Fig. [2c](#Fig2){ref-type="fig"}).

Blinded analysis of the neuronal fluorescence in general, but also the presence of homogenous immunofluorescence close to the cell membrane, showed significant difference between control groups (pre-treatment and repeated treatment with saline) and pre-treatment with KYNA analog (*p* \< 0.05). IL-1β immunoreactivity was significantly decreased in the repeated treatment KYNA group compared to control groups treated with saline (*p* \< 0.001). Between the pre-treated and repeated treatment groups, no significant difference could be noted (*p* = 0.969).

A schematic drawing of the main results for the immunohistochemistry is shown in Fig. [4](#Fig4){ref-type="fig"} and results are summarized in Table [3](#Tab3){ref-type="table"}.Fig. 4A schematic drawing of the distribution of pERK1/2 and IL-1βTable 3Summary of results for IHC for pERK and IL-1β regarding neurons, fibers and satellite glial cells (SGC); intensity scale: "-" no staining, "+/-" very weak staining, "+"-weak staining, "++"-moderate staining, "+++" strong stainingpERK 1/2IL-1βGroupsNeurons (nucleolei)FibersSGCNeuronsFibersSGCPre-treatment SZR72 (dura exposed to CFA)+++/-+/-+-Pre-treatment saline (dura exposed to CFA)+++++++++-Repeated treatment SZR72 (dura exposed to CFA)+++++/-+-Repeated treatment saline (dura exposed to CFA)+++++++++-Intact control (unoperated)+++/\--+-

Western blot {#Sec14}
------------

Staining for both pERK/tERK and pro-IL-1β using tissue lysates of complete left trigeminal ganglia did not reveal any significant changes in expression levels between treatment groups as analyzed by one-way ANOVA (*p* = 0.8282 and *p* = 0.7461, respectively) with Bonferroni multiple correction post-testing and Student's t-test (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Western blot of pERK, t-ERK and IL-1β in the whole trigeminal ganglion revealing no significant difference between the treatment groups

Discussion {#Sec15}
==========

The main question asked was if the KYNA derivate could modify the CFA-induced long-term inflammatory activation of the trigeminal ganglion, shown by increased expression of pERK1/2 and IL-1β \[[@CR12]\].

The role of the kynurenine pathway in the CNS is very complex, modulating several neurotransmitters. In 1947 Beadle at al. \[[@CR15]\] discovered that the major route for tryptophan metabolism to nictoniamide and its conjugates is the kynurenine pathway. Tryptophan represents a precursor of serotonin, a neurotransmitter playing an important role in the migraine pathophysiology \[[@CR16]\]. The kynurenine pathway, having several neuroactive metabolites including kynurenic acid (KYNA) \[[@CR17], [@CR18]\], has an important role in various diseases of the CNS \[[@CR6], [@CR19]\]. Astrocytes represent one source of neuroprotective KYNA \[[@CR6], [@CR20]\]; KYNA was presumed to have protective effect in neuronal cell death \[[@CR21], [@CR22]\]. Studies have also suggested that an elevated extracellular KYNA level would be needed to act more effectively \[[@CR23]\], leading to the idea of systemic administration of KYNA. This was not proved to be an ideal therapeutic option, as KYNA poorly penetrates the blood-brain barrier and it undergoes a rapid clearance from the brain and the circulation \[[@CR24]\]. To overcome these difficulties new KYNA analogues were synthesized to facilitate blood-brain penetration \[[@CR13]\]. It has been shown that the analogue SZR72 has similar neuroprotective effect as KYNA and cross more easily the BBB \[[@CR25], [@CR26]\].

In the present study SZR72 (1 mmol/kg bodyweight) reduced the CFA- elevated response on pERK1/2 and IL-1β activation in the trigeminal ganglion. The experiments were designed to answer the question if in case of chronification of migraineous mechanism (i) one dose of SZR72 is enough to attenuate the activation or if (ii) daily treatment would be needed.

The pERK1/2 is suggested to represent a rapid and robust marker of activation and inflammation \[[@CR27], [@CR28]\], whereas IL-1β is a late marker of maintained neuropathic pain \[[@CR29]\]. In case of using one dose of SZR72, pERK1/2 activation in the SGC was significantly diminished, whereas in case of repeated treatment the difference was not found to be significant. This finding might be explained by the property of pERK1/2 as being an early marker and not an optimal sign of prolonged activation.

The IL-1β activation was modified both after one dose of SZR72 and after repeated treatment with SZR72. Although no significant difference was observed between the pre-treatment and repeated treatments in case of IL-1β, there was a significant difference between the repeated SZR72 treated group and control groups. IL-1β might represent a more proper marker to examine long term effects of SZR72.

When it comes to our Western blot studies, the same tendency can be followed, without any significant difference between the groups. This might be explained by a methodological problem: to isolate macroscopically the V1 region is almost impossible therefor**e** the whole ganglia were processed in case of WB studies. We might reasonably postulate that our WB studies are not specific enough for the V1 region of the trigeminal ganglion.

In conclusion, this is the first study to address the question whether daily use of the new KYNA analog would be more effective than one dose prior activation in a chronification model of trigeminal activation. Pretreatment with one dose was able to abolish pERK and IL-1β activation in the trigeminal ganglion. These findings open a new line for further investigations which could result in a new way to modulate inflammation in chronic migraine.
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